Cellebrite DI (NASDAQ:CLBT) Given New $23.00 Price Target at Lake Street Capital

Cellebrite DI (NASDAQ:CLBT) had its price objective boosted by Lake Street Capital from $22.00 to $23.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital’s price objective would indicate a potential upside of 20.14% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC lifted their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, November 7th. Finally, Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded up $3.18 during midday trading on Thursday, reaching $19.15. 3,158,082 shares of the stock traded hands, compared to its average volume of 1,638,035. The stock has a market capitalization of $4.58 billion, a P/E ratio of -25.26, a PEG ratio of 3.16 and a beta of 1.28. The company has a fifty day moving average of $17.72 and a 200 day moving average of $16.69. Cellebrite DI has a 12 month low of $13.10 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI’s revenue was up 17.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 EPS. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Large investors have recently made changes to their positions in the company. Pertento Partners LLP increased its position in shares of Cellebrite DI by 57.8% during the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock valued at $86,131,000 after purchasing an additional 1,702,574 shares during the last quarter. Capital Research Global Investors grew its position in Cellebrite DI by 42.3% during the third quarter. Capital Research Global Investors now owns 2,425,736 shares of the company’s stock valued at $44,949,000 after buying an additional 721,154 shares during the period. Vestcor Inc purchased a new stake in Cellebrite DI during the third quarter valued at approximately $70,000. Swiss National Bank raised its position in Cellebrite DI by 1.4% in the third quarter. Swiss National Bank now owns 210,100 shares of the company’s stock worth $3,893,000 after acquiring an additional 3,000 shares during the period. Finally, Blair William & Co. IL boosted its stake in shares of Cellebrite DI by 3.9% during the 3rd quarter. Blair William & Co. IL now owns 89,425 shares of the company’s stock worth $1,657,000 after acquiring an additional 3,398 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.